Related Experiment Video
Updated: Jun 16, 2026
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside
Munira Shabbir1, Robert Stuart
1Medical University of South Carolina, Hematology and Oncology, 96 Jonathan Lucas Street, CSB 903, Charleston, SC 29425, USA.
Expert Opinion on Investigational Drugs
|February 10, 2010
Summary
Lestaurtinib shows promise as a targeted therapy for acute myeloid leukemia (AML) with FLT3-ITD mutations. Ongoing clinical trials are evaluating its efficacy, particularly in combination with chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Internal tandem duplication of the fms-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) is a common mutation in acute myeloid leukemia (AML).
- FLT3-ITD mutations confer a poor prognosis in AML patients with normal karyotype.
- Lestaurtinib (CEP-701) is a potent FLT3 inhibitor developed for AML treatment.
Purpose of the Study:
- To review the historical development of lestaurtinib.
- To summarize preclinical and clinical data on lestaurtinib.
- To explore future directions for lestaurtinib in AML treatment.
Main Methods:
- Extensive literature search of preclinical and clinical studies on lestaurtinib.
- Review spanned the last decade of research.
- Included published articles and abstracts.
Main Results:
- Lestaurtinib potently inhibits FLT3 at nanomolar concentrations.
- Phase I studies indicate lestaurtinib is an active agent, especially with cytotoxic drugs.
- Ongoing Phase II and III studies aim to establish its role in FLT3-ITD AML.
Conclusions:
- Lestaurtinib is a multi-targeted tyrosine kinase inhibitor with potential in FLT3-ITD AML.
- Its development is driven by potent FLT3 inhibition.
- Further clinical trials are crucial to define its therapeutic value.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: